Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 9 |
List of Tables | 9 | 1 |
List of Figures | 10 | 1 |
Introduction | 11 | 1 |
Global Markets Direct Report Coverage | 11 | 1 |
Cancer Pain Overview | 12 | 1 |
Therapeutics Development | 13 | 2 |
Pipeline Products for Cancer Pain Overview | 13 | 1 |
Pipeline Products for Cancer Pain Comparative Analysis | 14 | 1 |
Cancer Pain Therapeutics under Development by Companies | 15 | 2 |
Cancer Pain Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
Cancer Pain Pipeline Products Glance | 18 | 4 |
Late Stage Products | 18 | 1 |
Clinical Stage Products | 19 | 1 |
Early Stage Products | 20 | 1 |
Unknown Stage Products | 21 | 1 |
Cancer Pain Products under Development by Companies | 22 | 3 |
Cancer Pain Products under Investigation by Universities/Institutes | 25 | 1 |
Cancer Pain Companies Involved in Therapeutics Development | 26 | 34 |
Alexza Pharmaceuticals Inc | 26 | 1 |
AngioChem Inc | 27 | 1 |
Aoxing Pharmaceutical Company Inc | 28 | 1 |
Aphios Corp | 29 | 1 |
AstraZeneca Plc | 30 | 1 |
Benitec Biopharma Ltd | 31 | 1 |
BioDelivery Sciences International Inc | 32 | 1 |
ChironWells GmbH | 33 | 1 |
Colby Pharmaceutical Company | 34 | 1 |
Daiichi Sankyo Company Ltd | 35 | 1 |
Dompe Farmaceutici SpA | 36 | 1 |
Fujimoto Pharmaceutical Corp | 37 | 1 |
Grunenthal GmbH | 38 | 1 |
GW Pharmaceuticals Plc | 39 | 1 |
Hisamitsu Pharmaceutical Co Inc | 40 | 1 |
Immupharma Plc | 41 | 1 |
IntelGenx Corp | 42 | 1 |
iX Biopharma Ltd | 43 | 1 |
Kancera AB | 44 | 1 |
Klaria Pharma Holding AB | 45 | 1 |
Komipharm International Co Ltd | 46 | 1 |
KPI Therapeutics Inc | 47 | 1 |
Neurocentrx Pharma Ltd | 48 | 1 |
Nippon Kayaku Co Ltd | 49 | 1 |
Orion Oyj | 50 | 1 |
Pain Therapeutics Inc | 51 | 1 |
Pfizer Inc | 52 | 1 |
Pharmaleads SA | 53 | 1 |
Recordati SpA | 54 | 1 |
Ribomic Inc. | 55 | 1 |
Trillium Therapeutics Inc | 56 | 1 |
Virobay Inc | 57 | 1 |
WEX Pharmaceuticals Inc | 58 | 1 |
Zynerba Pharmaceuticals Inc | 59 | 1 |
Cancer Pain Therapeutics Assessment | 60 | 11 |
Assessment by Monotherapy Products | 60 | 1 |
Assessment by Target | 61 | 3 |
Assessment by Mechanism of Action | 64 | 3 |
Assessment by Route of Administration | 67 | 2 |
Assessment by Molecule Type | 69 | 2 |
Drug Profiles | 71 | 70 |
ANG-2002 Drug Profile | 71 | 1 |
AQU-118 Drug Profile | 72 | 1 |
AZD-8797 Drug Profile | 73 | 2 |
BBI-11008 Drug Profile | 75 | 1 |
buprenorphine hydrochloride Drug Profile | 76 | 1 |
cebranopadol Drug Profile | 77 | 3 |
CPC-111 Drug Profile | 80 | 1 |
crotalphine Drug Profile | 81 | 1 |
CSTI-200 Drug Profile | 82 | 1 |
dexmedetomidine hydrochloride Drug Profile | 83 | 2 |
dronabinol Drug Profile | 85 | 1 |
Drug 1 for Migraine and Cancer Pain Drug Profile | 86 | 1 |
Drug 2 for Migraine and Cancer Pain Drug Profile | 87 | 1 |
Drug 3 for Migraine and Cancer Pain Drug Profile | 88 | 1 |
Drug for Cancer Neuropathic Pain Drug Profile | 89 | 1 |
Drug for Migraine and Cancer Pain Drug Profile | 90 | 1 |
fentanyl Drug Profile | 91 | 1 |
fentanyl citrate Drug Profile | 92 | 2 |
fentanyl citrate Drug Profile | 94 | 1 |
fentanyl citrate Drug Profile | 95 | 1 |
fentanyl citrate ER Drug Profile | 96 | 1 |
gabapentin Drug Profile | 97 | 1 |
HP-3150 Drug Profile | 98 | 1 |
HS-198 Drug Profile | 99 | 1 |
hydromorphone hydrochloride Drug Profile | 100 | 1 |
HYLP-002 Drug Profile | 101 | 1 |
INT-0010 Drug Profile | 102 | 1 |
IPP-102199 Drug Profile | 103 | 1 |
methadone hydrochloride Drug Profile | 104 | 1 |
nabiximols Drug Profile | 105 | 7 |
Nervarna Drug Profile | 112 | 1 |
PAX-1 Drug Profile | 113 | 1 |
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain Drug Profile | 114 | 1 |
Peptide to Target CANP for Cardiovasclar and Cancer Pain Drug Profile | 115 | 1 |
PL-265 Drug Profile | 116 | 1 |
QX-314 Drug Profile | 117 | 1 |
RBM-004 Drug Profile | 118 | 1 |
RBM-007 Drug Profile | 119 | 1 |
resiniferatoxin Drug Profile | 120 | 2 |
saracatinib difumarate Drug Profile | 122 | 2 |
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 124 | 1 |
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 125 | 1 |
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 126 | 1 |
Small Molecules for Pancreatic Cancer and Perineural Invasion Drug Profile | 127 | 1 |
tanezumab Drug Profile | 128 | 3 |
Tetrodotoxin Drug Profile | 131 | 2 |
tilidine hydrochloride Drug Profile | 133 | 1 |
U-2902 Drug Profile | 134 | 2 |
VBY-825 Drug Profile | 136 | 1 |
zucapsaicin Drug Profile | 137 | 2 |
ZYN-001 Drug Profile | 139 | 2 |
Cancer Pain Dormant Projects | 141 | 4 |
Cancer Pain Discontinued Products | 145 | 1 |
Cancer Pain Product Development Milestones | 146 | 10 |
Featured News &Press Releases | 146 | 1 |
Sep 30, 2016: Grunenthal s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain | 146 | 1 |
Mar 31, 2016: Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride | 146 | 1 |
Oct 27, 2015: GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex Phase 3 Cancer Pain Trials | 147 | 1 |
Sep 08, 2015: Kancera evaluates immuno-oncology drug candidate | 148 | 1 |
Aug 13, 2015: Biodelivery Sciences Announces FDA Approval Of New Formulation Of Onsolis (Fentanyl Buccal Soluble Film) CII | 149 | 1 |
Jan 27, 2015: BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda | 150 | 1 |
Apr 28, 2014: Hospira Files Petition Against Aurobindo Over Patent Infringement | 150 | 1 |
Apr 28, 2014: GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain | 151 | 1 |
Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation | 151 | 1 |
Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex | 152 | 1 |
Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan | 152 | 1 |
Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation | 153 | 1 |
Feb 14, 2013: US Federal Court Validates Cephalon s Fentora Patents | 153 | 1 |
Oct 15, 2012: BioDelivery Sciences Announces Launch Of Breakyl In EU | 154 | 1 |
Jul 11, 2012: Taiho And Teikoku Form Business Partnership For Pain Reliever OVF | 154 | 2 |
Appendix | 156 | 2 |
Methodology | 156 | 1 |
Coverage | 156 | 1 |
Secondary Research | 156 | 1 |
Primary Research | 156 | 1 |
Expert Panel Validation | 156 | 1 |
Contact Us | 156 | 1 |
Disclaimer | 157 | 1 |